Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V. Sequist, Geoffrey R. Oxnard, Helena A. Yu et al.|The Lancet Oncology|2020Cited by 413
Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancerSeok-Ki Kim, Jae-Moon Bae, Keon Wook Kang et al.|European Journal of Nuclear Medicine and Molecular Imaging|2005Cited by 175
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines releaseKoung Jin Suh, Jong Seok Lee|Oncotarget|2017Cited by 46